Showing 15 posts of 21 posts found.


Mylan and Biocon’s Semglee, biosimilar to Sanofi’s Lantus, approved by FDA for type 1 and 2 diabetes

June 12, 2020
Medical Communications, Sales and Marketing FDA, Lantus, Mylan Biocon, Sanofi, Semglee, diabetes

Mylan and Biocon have scored FDA approval with their insulin glargine injection Semglee, a biosimilar to Sanofi’s Lantus, in both …


MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes

October 15, 2018
Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma

MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …

Sanofi Q3 results disappoint due to waning diabetes sales

November 2, 2017
Sales and Marketing Lantus, Sanofi, diabetes, pharma

Sanofi readjusted its 2017 financial expectations after its third-quarter results came in lower than projected. The company revealed that net …

Sanofi launches patent infringement lawsuit against Mylan over diabetes pen

October 25, 2017
Research and Development, Sales and Marketing Basaglar, Eli Lilly, Lantus, Mylan, Sanofi, diabetes, insulin, patent infringement, pharma

Sanofi has launched a lawsuit against Mylan as part of a dispute that alleges that the latter infringed upon 18 …


Sanofi reveals promising data for FDA-delayed diabetes drug

September 14, 2016
Research and Development, Sales and Marketing FDA, Lantus, Sanofi, iglarlixi

Sanofi has announced new Phase III data for its IGlarLixi combination drug for the treatment of diabetes, showing it could …


MSD files Lantus biosimilar with FDA

August 8, 2016
Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar

MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …


FDA to decide on Sanofi diabetes combo

February 22, 2016
Research and Development, Sales and Marketing Lantus, Sanofi

Sanofi will be looking to August for a decision on its new type 2 diabetes combo LixiLan (lixisenatide and Lantus), …

FDA sign

FDA approves Lilly/Boehringer Lantus biosimilar

December 17, 2015
Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly

The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …


Sanofi’s LixiLan meets target in Phase III diabetes trial

September 16, 2015
Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes

Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …


Lilly and Boehringer launch biosimilar insulin in the UK

August 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …

Toujeo pen

Sanofi launches new insulin Toujeo in the UK

August 4, 2015
Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo

Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …

Sanofi image

Sanofi rules out Toujeo discount in diabetes

April 14, 2015
Sales and Marketing 100 U/mL, Boehringer, Lantus, insulin glargine [rDNA origin] injection, lilly, toujeo

Sanofi has revealed that it will not discount its new insulin Toujeo more than its current blockbuster Lantus, despite lacking …

Sanofi image

Sanofi sales lifted by diabetes and rare diseases

February 6, 2015
Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4

Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …

France Focus: Power without responsibility?

October 27, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing France, Lantus, Sanofi, Servier, hollande, perindopril, report

Population: 65.8 million (2013) Government: Unitary semi-presidential constitutional republic Leader: François Hollande of the centre-left Socialist Party Gross Domestic Product: …

Lilly image

Lilly and Boehringer diabetes biosimilar sees EU approval

September 11, 2014
Sales and Marketing Boehringer, EU, European Commission, Lantus, Sanofi, diabetes, lilly

Lilly and Boehringer Ingelheim’s insulin glargine product has been shown the green light by the European Commission (EC). The copycat …

Latest content